ClinicalTrials.Veeva

Menu

Improvement of Understanding of Pediatric Sacral Neuromodulation: Therapeutic Strategies and Outcome Variables (SMART-GUT)

F

Friedrich-Alexander-Universität Erlangen-Nürnberg

Status

Enrolling

Conditions

Hirschsprung Disease
Constipation - Functional
Gastrointestinal Motility Disorders in Children

Treatments

Procedure: SNM/MRI/EMG

Study type

Interventional

Funder types

Other

Identifiers

NCT07519915
SMART-GUT_V1

Details and patient eligibility

About

The goal of this study is to learn about the effects of sacral neuromodulation in pediatric patients with gastrointestinal motility disorders. By combining advanced neuroimaging, patient-specific biophysical modeling, electrophysiological characterization, and clinical translation, the SMART-GUT project establishes a comprehensive framework to systematically investigate neuromodulation in this pediatric population. This integrative approach enables a direct link between mechanism, targeting, and clinical outcome.

Full description

Patients enrolled in the study will be receiving sacral neuromodulation (via surgical implantation) and MRIs prior to neuromodulation treatment and after 12 weeks. In cases of surgical implantation, the intraoperative testing is accompanied by a broad neuronal evaluation (The goal is to establish with these informations

  • improved understanding of interindividual sacral nerval anatomy
  • improved guidelines for implantation of sacral neuromodulation via 3D reconstructions (digital twins)
  • prediction of neural activation by sacral neuromodulation and improvement of response rates
  • mechanism guided implantation based on clinical symptoms (fecal incontinence vs. leading constipative symptoms)
  • improvement of therapeutic efficacy in comparison to non-guided implantation

Enrollment

25 estimated patients

Sex

All

Ages

3 to 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • informed consent of patient and care taker
  • gastrointestinal motility disorder, disregarding underlying diseases
  • exclusion of mechanical obstructions in the gastrointestinal passage
  • age between 3 and 18

Exclusion criteria

  • pregnancy/breast feeding
  • decreased renal or thyroidal function
  • drug intake of Beta-blockers, antispasmodics, cyclopropane, bisulfite compounds, haloperidol, heroin, meperidine, metamizole, methadone, morphine, nitrofurantoin, opium alkaloids, phenobarbital, phenylbutazone, probenecid, rifamycin
  • contradictions for MRI
  • indication for analgosedation for MRI
  • inflammatory bowel diseases
  • fractures/different anatomy in sacral region
  • epilepsy
  • presence of cardiac pacemakers

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Sequential Assignment

Masking

None (Open label)

25 participants in 2 patient groups

SNM-guided implantation
Active Comparator group
Description:
Surgical implantation of sacral neuromodulation after generation of digital twin and intraoperative efficacy testing
Treatment:
Procedure: SNM/MRI/EMG
SNM
No Intervention group
Description:
SNM implantation based on general knowledge and adult measurements

Trial contacts and locations

1

Loading...

Central trial contact

Sonja Diez, PD Dr. med.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems